Reversibility and recurrence of IGF-IR-induced mammary tumors

[1]  J. Petrik,et al.  Characterization of a Novel Primary Mammary Tumor Cell Line Reveals that Cyclin D1 Is Regulated by the Type I Insulin-Like Growth Factor Receptor , 2008, Molecular Cancer Research.

[2]  H. Varmus,et al.  Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras , 2008, Proceedings of the National Academy of Sciences.

[3]  P. V. van Diest,et al.  Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. , 2008, Biochemical and biophysical research communications.

[4]  G. Kirby,et al.  Expression of cytochrome P450 2A5 in a glucose-6-phosphate dehydrogenase-deficient mouse model of oxidative stress. , 2008, Biochemical pharmacology.

[5]  R. Cardiff,et al.  Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16 Ink4a loss. , 2008, The Journal of clinical investigation.

[6]  J. Aguirre-Ghiso,et al.  Models, mechanisms and clinical evidence for cancer dormancy , 2007, Nature Reviews Cancer.

[7]  J. Clements,et al.  Epithelial—mesenchymal and mesenchymal—epithelial transitions in carcinoma progression , 2007, Journal of cellular physiology.

[8]  A. Adjei,et al.  Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors , 2007, Clinical Cancer Research.

[9]  D. Ludwig,et al.  IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor , 2007, Clinical Cancer Research.

[10]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[11]  Héctor Peinado,et al.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? , 2007, Nature Reviews Cancer.

[12]  R. Nahta,et al.  Trastuzumab: triumphs and tribulations , 2007, Oncogene.

[13]  J. Kurebayashi.  Current clinical trials of endocrine therapy for breast cancer , 2007, Breast cancer.

[14]  L. Chodosh,et al.  Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation , 2007, Oncogene.

[15]  John J Rossi,et al.  MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-β-induced collagen expression via inhibition of E-box repressors , 2007, Proceedings of the National Academy of Sciences.

[16]  E. Thompson,et al.  Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. , 2006, Cancer research.

[17]  Adrian V. Lee,et al.  The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth , 2006, Breast Cancer Research and Treatment.

[18]  Yang Feng,et al.  Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function , 2006, Molecular Cancer Therapeutics.

[19]  F. Speleman,et al.  RTPrimerDB: the real-time PCR primer and probe database, major update 2006 , 2005, Nucleic Acids Res..

[20]  Robert D Cardiff,et al.  The transcriptional repressor Snail promotes mammary tumor recurrence. , 2005, Cancer cell.

[21]  R. Moorehead,et al.  Use of a transgenic mouse model to identify markers of human lung tumors , 2005, International journal of cancer.

[22]  Adrian V. Lee,et al.  Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. , 2005, Cancer research.

[23]  G. Berx,et al.  DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells , 2005, Oncogene.

[24]  P. Pauwels,et al.  A recombinant humanized anti‐insulin‐like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti‐epidermal growth factor receptor therapy against human cancer xenografts , 2005, International journal of cancer.

[25]  Robert B Boxer,et al.  Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. , 2004, Cancer cell.

[26]  S. Hankinson,et al.  Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.

[27]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[28]  Matthias Egger,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.

[29]  T. Libermann,et al.  Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. , 2004, Cancer cell.

[30]  Peter Bohlen,et al.  A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. , 2003, Cancer research.

[31]  Robert D Cardiff,et al.  Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. , 2003, Genes & development.

[32]  Mitchell D Schnall,et al.  Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. , 2002, Cancer cell.

[33]  Simak Ali,et al.  Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.

[34]  Y. Lu,et al.  Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.

[35]  Ennis,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[36]  R. Cardiff,et al.  c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations , 2001, Nature Medicine.

[37]  H. Tan,et al.  Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo , 2000, Cancer Gene Therapy.

[38]  Kristen L Murphy,et al.  Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis , 2000, Oncogene.

[39]  J. Zalcberg,et al.  Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line , 1999, British Journal of Cancer.

[40]  Sandra,et al.  A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. , 1998, Cancer research.

[41]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[42]  D. Pravtcheva,et al.  Metastasizing mammary carcinomas in H19 enhancers-Igf2 transgenic mice. , 1998, The Journal of experimental zoology.

[43]  N. Webster,et al.  Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. , 1998, Cancer research.

[44]  D. Hill,et al.  Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II) , 1995, British Journal of Cancer.

[45]  C. Singer,et al.  Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function. , 1995, Cancer research.

[46]  C. Osborne,et al.  Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. , 1989, The Journal of clinical investigation.

[47]  D. Yee,et al.  Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. , 1989, Molecular endocrinology.

[48]  D. Yee,et al.  Insulin-like growth factor II mRNA expression in human breast cancer. , 1988, Cancer research.

[49]  D. Campani,et al.  IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: Anin situ hybridization and immunohistochemistry study , 2005, Breast Cancer Research and Treatment.

[50]  S. Paik.  Expression of IGF-I and IGF-II mRNA in breast tissue , 2005, Breast Cancer Research and Treatment.

[51]  E. Surmacz.  Function of the IGF-I Receptor in Breast Cancer , 2004, Journal of Mammary Gland Biology and Neoplasia.